Nippon Shinyaku has entered into an option agreement with Elixirgen Therapeutics under which it may obtain exclusive worldwide rights to develop and commercialise EXG-7001 for the treatment of Duchenne muscular dystrophy.

• Agreement Scope: The option agreement covers the potential exclusive worldwide development and commercialisation rights for EXG-7001, an investigational mRNA-based therapeutic for Duchenne muscular dystrophy.
• Drug Candidate: EXG-7001 is a locally administered, mRNA-based therapeutic designed to express full-length human dystrophin protein and is currently in preclinical development.
• Development Status: Elixirgen is preparing for clinical trials in the United States, while commercialisation by Nippon Shinyaku would be subject to the exercise of the option rights and regulatory approval.

This summary is based on a news report published by BioSpectrum Asia.

Image for illustrative purposes only. Source: Canva.

About Ehub365

For Corporate Clients, ehub365 division delivers critical insights into the ASEAN medical sector, covering investments, new services, and practitioner news. 

A member of 365Asia. Our additional group services are Health365, 365Asia, 健康365, 365Sehat, and 365MEC.